 ROCKVILLE, Md. and BEIJING, March 23, 2021 PRNewswire -- CASI Pharmaceuticals, Inc. Nasdaq: CASI, a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. 